NEW YORK, NY--(Marketwire -04/24/12)- Mergers and Acquisitions have been a hot topic in the Biotechnology Industry recently. Pharmaceutical giants face an unprecedented number of patent expirations for its pharmaceutical products between 2009 and 2013. It is apparent that pharmaceutical companies have begun to make strategic decisions to combat the anticipated losses. The Paragon Report examines investing opportunities in the Biotechnology Industry and provides equity research on Dendreon Corporation (NASDAQ: DNDN - News) and Galena Biopharma Inc. (NASDAQ: GALE - News).
Access to full reports can be found at:
According to a recent report by Dealogic, pharmaceutical deals totaled $18.5 billion globally this year, an increase of 5% from the same period last year. As larger companies continue to reduce spending on research and development they continue to look at smaller biotech companies to diversify their product lines. Mergers & Acquisitions allows bigger companies to acquire products and technologies that are already proven in the market place, avoiding the many risks associated with research and development.
On Thursday Biotechnology Company Human Genome Sciences rejected a $2.59 billion takeover bid from GlaxoSmithKline. The announcement comes just a day after Swiss pharmaceutical company Roche announced that it was abandoning its bid for U.S. biotech firm Illumina.
Paragon Report releases regular market updates on the Biotechnology Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.ParagonReport.com and get exclusive access to our numerous stock reports and industry newsletters.
Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development, commercialization and manufacturing of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy (ACI) product candidates designed to stimulate an immune response in a variety of tumor types. Dendreon's first product, PROVENGE (sipuleucel-T), was approved by the U.S. Food and Drug Administration (FDA) in April 2010.
Galena Biopharma, Inc., a biotechnology company, engages in discovering, developing, and commercializing innovative therapies addressing unmet medical needs using targeted bio therapeutics. Last month Galena announced that the U.S. Patent and Trademark Office agreed to award it another patent on NeuVax as a treatment for breast cancer. The patent covers the use of NeuVax in women with HER-2 positive breast cancer.
Paragon Report provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. The Paragon Report has not been compensated by any of the above-mentioned companies. We act as independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at: www.ParagonReport.com/disclaimer